Background
Shane has a Bachelor of Science (Hons) in Immunology from Monash University. In 2002, he completed his PhD in the fields of hepatology and endocrinology where some of his work contributed to the establishment of Paranta Biosciences.
For the last 18 years Shane has worked in the pharmaceutical industry for several multinational companies, including GSK, Roche, MSD and Gilead, where he developed expertise in Regulatory Affairs, Marketing and Medical Affairs. In this time he also established a consulting agency, Pantheon Consulting.
Shane has worked in a diverse range of therapy areas including vaccines, oncology, infectious diseases (viral hepatitis and HIV), diabetes, cardiovascular, neuroscience and rare disease therapeutic areas where he contributed to the launch of over 15 medications or diagnostic tests in the Asia-Pacific region.
Shane is a graduate of the Australian Institute of Company Directors and is currently a non-executive director of LiverWELL (incorporating Hepatitis Victoria), a sessional lecturer at Monash University and a member of the Deakin University School of Life Sciences Advisory Board.
Qualifications
- Bachelor of Science (Honours), Department of Immunology and Pathology, Monash University, Australia
- Doctorate of Philosophy, Department of Medicine, Monash University, Australia
- AICD Company Directors Diploma, Australian Institute of Company Directors.
Appointments
- Non-executive Director, LiverWELL
- Advisory Board Member, School of Life Sciences, Deakin University
- Sessional Lecturer, Monash University.
Current projects
EXPAND-C: hepatitis C testing and treatment through community pharmacies
Expanding access to hepatitis C testing and treatment using a pharmacy-based model.
Liver health screening test
A rapid point-of-care (POC) test for liver disease biomarkers could improve the management of acute and chronic liver disease and reduce the progression to liver cancer in Australia and globally.